Unanticipated plasma concentrations in two clozapine-treated patients

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1028-1031

  Alfaro, Cara L ^a   McClure, Robert K ^a   Vertrees, Julia E ^b   Benavides, Ray ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Clozapine; Cytochrome P450; Therapeutic drug monitoring

Indexed keywords

CLOZAPINE; CYTOCHROME P450;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT PLANNING;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; SCHIZOPHRENIA;

EID: 0034822941     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10227     Document Type: Article

References (21)

1. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients
2. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics
3. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
4. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
5. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia
6. Therapeutic drug monitoring of clozapine treatment: Therapeutic threshold value for serum clozapine concentrations
7. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges
8. Influence of patient-related variables on clozapine plasma levels
9. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients
10. CYP1A2 activity predicts the clozapine steady-state concentration in schizophrenic patients
11. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine
12. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients
13. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
14. Fluvoxamine reduces the clozapine dose needed in refractory schizophrenic patients
15. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
16. N-desmethylclozapine: A clozapine metabolite that suppresses haemopoesis
17. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis
18. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
19. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report
20. Time to clozapine response in a standardized trial
21. How long to wait for a response to clozapine: A comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia